Drug Patent Expirations in November 2009

The following drugs face patent expirations in November 2009

Applicant :: TRADENAME :: generic name

Pfizer :: TROVAN PRESERVATIVE FREE :: alatrofloxacin mesylate
Teva Global :: PROAIR HFA :: albuterol sulfate
3m :: PROVENTIL-HFA :: albuterol sulfate
Takeda Pharms Na :: PREVPAC :: amoxicillin; clarithromycin; lansoprazole
Teva Global :: QVAR 40 :: beclomethasone dipropionate
Teva Global :: QVAR 80 :: beclomethasone dipropionate
Boehringer Ingelheim :: ATROVENT HFA :: ipratropium bromide
Allergan :: ACULAR :: ketorolac tromethamine
Allergan :: ACULAR LS :: ketorolac tromethamine
Takeda Pharms Na :: PREVACID :: lansoprazole
Takeda Pharms Na :: PREVACID IV :: lansoprazole
Takeda Pharms Na :: PREVACID NAPRAPAC 500 (COPACKAGED) :: lansoprazole; naproxen
Sepracor :: XOPENEX HFA :: levalbuterol tartrate
Ekr Therap :: CARDENE :: nicardipine hydrochloride
Solvay Pharms :: ACEON :: perindopril erbumine
R Tech Ueno Ltd :: RESCULA :: unoprostone isopropyl

This list does not discriminate between dominant and non-dominant patents. Listed drugs above may be protected by additional patents and other regulatory protections.

For more details, visit DrugPatentWatch at http://www.DrugPatentWatch.com 

To subscribe to the free Patent Expiration Bulletin, visit http://www.DrugPatentWatch.com/newsletter 

Disclaimer:
All trademarks and applicant names are the property of their respective owners or licensors. Drug patent expiration data is presented "as is." Use of this information is at your own risk. No warranty is expressed or implied. There is no warranty that the drug patent expriation information is error free.

---
ABOUT DrugPatentWatch ( http://www.DrugPatentWatch.com  )

DrugPatentWatch provides information on drug patents and their expirations. Datasets include Paragraph IV challenges, patent claim types, annual sales, patent expirations, failure to pay maintenance fees, ex parte and inter partes reexamination, interference, and disclaimers. Complete details are provided for all FDA-approved small molecule drugs. Annual sales information is available for top-selling drugs. This value-added information supports the critical business functions of patent agents and attorneys, pharmaceutical companies, wholesalers, healthcare payers, and investors.